BR112013017933A2 - composição líquida e método para sua fabricação - Google Patents

composição líquida e método para sua fabricação

Info

Publication number
BR112013017933A2
BR112013017933A2 BR112013017933A BR112013017933A BR112013017933A2 BR 112013017933 A2 BR112013017933 A2 BR 112013017933A2 BR 112013017933 A BR112013017933 A BR 112013017933A BR 112013017933 A BR112013017933 A BR 112013017933A BR 112013017933 A2 BR112013017933 A2 BR 112013017933A2
Authority
BR
Brazil
Prior art keywords
compositions
manufacture
liquid composition
liquids
patient
Prior art date
Application number
BR112013017933A
Other languages
English (en)
Other versions
BR112013017933B1 (pt
Inventor
Edward D Gomperts
Henry J Forman
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of BR112013017933A2 publication Critical patent/BR112013017933A2/pt
Publication of BR112013017933B1 publication Critical patent/BR112013017933B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/40—Mixing liquids with liquids; Emulsifying
    • B01F23/45—Mixing liquids with liquids; Emulsifying using flow mixing
    • B01F23/454—Mixing liquids with liquids; Emulsifying using flow mixing by injecting a mixture of liquid and gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição líquida e método para sua fabricação a presente invenção refere-se a composições e métodos para a distribuição de monóxido de carbono (co) a sujeitos que sofrem de doenças inflamatórias, cardiovasculares, falciforme e outras doenças. as composições são líquidos, incluindo líquidos newtonianos e líquidos não-newtonianos, tais como pastas, géis, espumas, emulsões e outras composições não gasosas, nas quais o co é dissolvido em uma quantidade que, quando administrada a um paciente, fornece uma quantidade terapêutica ou profilaticamente eficaz de co ao paciente. as composições podem ser fornecidas em várias formas, incluindo em garrafas ou latas.
BR112013017933-3A 2011-01-14 2012-01-10 composição líquida e métodos para sua fabricação BR112013017933B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161432843P 2011-01-14 2011-01-14
US61/432,843 2011-01-14
US201161434639P 2011-01-20 2011-01-20
US61/434,639 2011-01-20
PCT/US2012/020710 WO2012096912A1 (en) 2011-01-14 2012-01-10 Solution of carbon monoxide for treatment of disease, including sickle cell disease

Publications (2)

Publication Number Publication Date
BR112013017933A2 true BR112013017933A2 (pt) 2016-07-12
BR112013017933B1 BR112013017933B1 (pt) 2021-02-23

Family

ID=46507397

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017933-3A BR112013017933B1 (pt) 2011-01-14 2012-01-10 composição líquida e métodos para sua fabricação

Country Status (8)

Country Link
US (3) US9980981B2 (pt)
EP (2) EP2663193B1 (pt)
JP (1) JP6118731B2 (pt)
CN (2) CN109925318A (pt)
BR (1) BR112013017933B1 (pt)
CA (1) CA2824056C (pt)
ES (1) ES2742829T3 (pt)
WO (1) WO2012096912A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2824056C (en) 2011-01-14 2019-01-08 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
CN107625954A (zh) * 2016-07-19 2018-01-26 上海本素医药科技有限公司 含一氧化碳的血红蛋白制剂及其在抗炎症中的应用
US20210228621A1 (en) * 2018-06-08 2021-07-29 Sumitomo Seika Chemicals Co., Ltd. Composition for skin wounds
CN112236150A (zh) * 2018-06-08 2021-01-15 住友精化株式会社 炎症性消化器官疾病用组合物
WO2022055991A1 (en) * 2020-09-08 2022-03-17 The Brigham And Women's Hospital, Inc. Therapeutic carbon monoxide formulations
WO2023249049A1 (ja) * 2022-06-23 2023-12-28 学校法人 愛知医科大学 腹膜劣化抑制組成物、腹膜劣化抑制組成物キット、腹膜透析液、および腹膜透析液キット
WO2024052570A1 (en) 2022-09-09 2024-03-14 Julius-Maximilians-Universität Würzburg Method for the preservation of functional gametes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407426A (en) 1991-02-14 1995-04-18 Wayne State University Method and apparatus for delivering oxygen into blood
US5261875A (en) 1991-02-14 1993-11-16 Wayne State University Method and apparatus for injection of gas hydrates
US5086620A (en) 1991-02-14 1992-02-11 Wayne State University Method of microencapsulation of hyperbaric gas
US6344489B1 (en) * 1991-02-14 2002-02-05 Wayne State University Stabilized gas-enriched and gas-supersaturated liquids
US5569180A (en) 1991-02-14 1996-10-29 Wayne State University Method for delivering a gas-supersaturated fluid to a gas-depleted site and use thereof
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US5834519A (en) 1996-10-11 1998-11-10 Wayne State University Stabilized gas-supersaturated emulsions and suspensions
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7238469B2 (en) * 2001-06-21 2007-07-03 Beth Israel Deaconess Medical Center, Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
AU2003208525B9 (en) * 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
KR20040096571A (ko) 2002-02-13 2004-11-16 베쓰 이스라엘 디코니스 메디칼 센터 인크 혈관 질환을 치료하는 방법
EP1499328B1 (en) * 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
MXPA04010243A (es) 2002-04-15 2005-07-05 Univ Pittsburgh Metodos para tratar ileo.
WO2003094932A1 (en) * 2002-05-09 2003-11-20 Yale University Carbon monoxide as a biomarker and therapeutic agent
CN1674922A (zh) * 2002-06-05 2005-09-28 耶鲁大学 治疗血管生成、肿瘤生长以及转移的方法
DE10230165A1 (de) * 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
EP1558084A4 (en) 2002-11-07 2008-04-30 Univ Pittsburgh TREATMENT OF HEMORRHAGIC SHOCK
US20080124436A1 (en) 2004-03-05 2008-05-29 Eldon Roth Method and apparatus for treating meat products with a treatment liquid containing carbon monoxide
US20060234915A1 (en) 2005-03-07 2006-10-19 Sangart, Inc. Compositions and methods for delivering carbon monoxide (CO) and nitric oxide (NO) to tissue using heme proteins as carriers
US7976743B2 (en) * 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
JP2008179569A (ja) 2007-01-25 2008-08-07 Tomohisa Takagi 薬剤及び薬剤の適用方法
EP2271750A4 (en) * 2008-03-24 2011-07-27 Althea Technologies Inc URICASE COMPOSITIONS AND METHODS OF USE
CN101590228A (zh) * 2008-05-26 2009-12-02 江苏大学附属医院 一氧化碳释放分子在制备早期治疗脓毒症药物中的应用
ES2966234T3 (es) 2009-06-09 2024-04-18 Prolong Pharmaceuticals Llc Composiciones de hemoglobina
US8500104B2 (en) * 2010-06-07 2013-08-06 James Richard Spears Pressurized liquid stream with dissolved gas
CA2824056C (en) 2011-01-14 2019-01-08 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease

Also Published As

Publication number Publication date
EP3583851A1 (en) 2019-12-25
WO2012096912A1 (en) 2012-07-19
US9980981B2 (en) 2018-05-29
EP2663193A4 (en) 2015-06-10
JP2014508135A (ja) 2014-04-03
CA2824056A1 (en) 2012-07-19
CN103491783A (zh) 2014-01-01
CN109925318A (zh) 2019-06-25
JP6118731B2 (ja) 2017-04-19
EP2663193A1 (en) 2013-11-20
US10716806B2 (en) 2020-07-21
US20180303872A1 (en) 2018-10-25
US20200297757A1 (en) 2020-09-24
BR112013017933B1 (pt) 2021-02-23
EP2663193B1 (en) 2019-05-08
ES2742829T3 (es) 2020-02-17
US20130309279A1 (en) 2013-11-21
CA2824056C (en) 2019-01-08

Similar Documents

Publication Publication Date Title
BR112013017933A2 (pt) composição líquida e método para sua fabricação
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
BR112015014372A2 (pt) inibidores de autotaxina
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
ECSP14004893A (es) Moléculas de unión para bcma y cd3
BR112015005048A2 (pt) métodos para tratar dermatite atópica por administração de antagonista il-4r
MX2013011922A (es) Compuestos de benceno substituido.
BR112013004750A2 (pt) derivados de quinolina e quinoxalina como inibidores da cinase
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
MY162146A (en) Pharmaceutical composition
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
MX2014010724A (es) Antibacterianos de fenicol.
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
CO7170174A2 (es) Formulación farmacéutica
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
CL2013002629A1 (es) Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc.
BR112015015341A2 (pt) composições para permeabilização de células sanguíneas fixadas e usos das mesmas
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
MX2015003192A (es) Composicion para su utilizacion como plasma de control anormal de la coagulacion de ensayos in vitro.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/01/2012, OBSERVADAS AS CONDICOES LEGAIS.